CDDF’s Selection As Ad Hoc Representative of the Multi-Stakeholder Platform Advisory Group (MSP AG) Under the Accelerating Clinical Trials in the EU (ACT EU)
The Cancer Drug Development Forum is proud to announce its selection as an ad hoc representative of the Multi-Stakeholder Platform Advisory Group (MSP AG) under the Accelerating Clinical Trials in the EU (ACT EU). The ACT EU initiative is run by the European...
Gain valuable perspectives from CDDF participants and get an inside look at the CDDF Multi-stakeholder workshop on Biomarkers in Precision Oncology (Nov 2023)
Take a look at the interviews with participants from the CDDF Multi-stakeholder Workshop on “Biomarkers in Delivering Drug Development-Related Precision Oncology (13-14 November 2023, Amsterdam) and gain valuable perspectives from diverse stakeholders. Collaboration...
NEW PUBLICATION-WHITE PAPER: Histology Independent Drug Development – Is This the Future for Cancer Drugs?
The Cancer Drug Development Forum (CDDF) is delighted to announce that the White Paper has been developed following its ‘Histology Independent Drug Development – Is This the Future for Cancer Drugs?’ workshop, which took place on 14-15th November 2022, in Amsterdam....
CDDF’s New Board Members: A Warm Welcome to Dr. Christian Schneider, Dr. Fergus Sweeney and Dr. Rosa Giuliani
With great pleasure, the Cancer Drug Development Forum (CDDF) announces the appointment of Dr. Christian Schneider, Dr. Fergus Sweeney, and Dr. Rosa Giuliani to its Board of Directors for a three-year term, effective 5 December, 2023. We warmly welcome these new...
Executive Summary of the CDDF Workshop on Biomarkers in Precision Oncology (13-14 Nov 2023, NL)
The Cancer Drug Development Forum (CDDF) is delighted to announce that its executive summary of the CDDF workshop on Biomarkers in Precision Oncology (13-14 Nov 2023, NL) has been published and is available to all our stakeholders. This insightful workshop brought...
TAKE-HOME MESSAGES: CDDF Multi-Stakeholder Workshop – The Critical Role of Biomarkers in Delivering Drug Development-Related Precision Oncology
Read the take-home messages from the CDDF multi-stakeholder workshop on The critical role of Biomarkers in delivering drug development-related precision oncology: SESSION 1: SETTING THE SCENE OF BIOMARKERS Key takeaways: Biomarkers are critical in the diagnosis...
Get an Inside Look at the CDDF Multi-Stakeholder Discussion on Innovative Oncology Trial Design
Watch the interviews with participants from the CDDF Multi-stakeholder Workshop on Innovative Oncology Trial Design (18-19 September 2023, Amsterdam) and gain valuable perspectives from diverse stakeholders in cancer drug development. Collaboration is key to...
CDDF’s New Publication: White Paper – “Empowering Involvement and Engagement of Patients with Cancer in Oncology Drug Development”
The CDDF is delighted to announce that the White Paper, “Empowering Involvement and Engagement of Patients with Cancer in Oncology Drug Development”, has been published in October 2023. It has been prepared by Prof. Mark Lawler on behalf of the Cancer Drug Development...
Key Takeaways from the CDDF Webinar on Perspectives on the new EU Health Technology Assessment HTA Regulation 2021/2282 (28 September 2023)
The Cancer Drug Development Forum (CDDF) held a live webinar on “Perspectives on the new EU Health Technology Assessment HTA Regulation 2021/2282 “ on Thursday 28 September 2023. In this webinar, Marcus Guardian and Julie Spony provided an overview of the topic...